This company has been marked as potentially delisted and may not be actively trading. Obalon Therapeutics (OBLN) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock OBLN vs. CATX, INFU, NSPR, CTCX, HSAQ, GBS, RVP, PETV, BTCY, and IVFShould you be buying Obalon Therapeutics stock or one of its competitors? The main competitors of Obalon Therapeutics include Perspective Therapeutics (CATX), InfuSystem (INFU), InspireMD (NSPR), Carmell (CTCX), Health Sciences Acquisitions Co. 2 (HSAQ), GBS (GBS), Retractable Technologies (RVP), PetVivo (PETV), Biotricity (BTCY), and INVO Fertility (IVF). These companies are all part of the "medical" sector. Obalon Therapeutics vs. Its Competitors Perspective Therapeutics InfuSystem InspireMD Carmell Health Sciences Acquisitions Co. 2 GBS Retractable Technologies PetVivo Biotricity INVO Fertility Perspective Therapeutics (NYSE:CATX) and Obalon Therapeutics (NASDAQ:OBLN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations. Which has more volatility and risk, CATX or OBLN? Perspective Therapeutics has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500. Comparatively, Obalon Therapeutics has a beta of -1.23, meaning that its stock price is 223% less volatile than the S&P 500. Do institutionals & insiders believe in CATX or OBLN? 54.7% of Perspective Therapeutics shares are owned by institutional investors. Comparatively, 18.6% of Obalon Therapeutics shares are owned by institutional investors. 3.7% of Perspective Therapeutics shares are owned by insiders. Comparatively, 8.1% of Obalon Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is CATX or OBLN more profitable? Obalon Therapeutics has a net margin of -776.76% compared to Perspective Therapeutics' net margin of -4,096.66%. Perspective Therapeutics' return on equity of -27.40% beat Obalon Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Perspective Therapeutics-4,096.66% -27.40% -23.16% Obalon Therapeutics -776.76%-161.38%-83.58% Do analysts prefer CATX or OBLN? Perspective Therapeutics presently has a consensus target price of $12.56, indicating a potential upside of 249.74%. Given Perspective Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Perspective Therapeutics is more favorable than Obalon Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Perspective Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 3 Strong Buy rating(s) 3.18Obalon Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has preferable valuation and earnings, CATX or OBLN? Obalon Therapeutics has higher revenue and earnings than Perspective Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPerspective TherapeuticsN/AN/A-$46.51MN/AN/AObalon Therapeutics$1.59M46.01-$12.33MN/AN/A Does the media prefer CATX or OBLN? In the previous week, Perspective Therapeutics had 2 more articles in the media than Obalon Therapeutics. MarketBeat recorded 2 mentions for Perspective Therapeutics and 0 mentions for Obalon Therapeutics. Perspective Therapeutics' average media sentiment score of 1.76 beat Obalon Therapeutics' score of 0.00 indicating that Perspective Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Perspective Therapeutics Very Positive Obalon Therapeutics Neutral SummaryPerspective Therapeutics beats Obalon Therapeutics on 10 of the 14 factors compared between the two stocks. Get Obalon Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OBLN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OBLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OBLN vs. The Competition Export to ExcelMetricObalon TherapeuticsSurgical & Medical Instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$73.16M$80.73M$5.75B$10.24BDividend YieldN/AN/A5.69%4.60%P/E Ratio-5.4111.5874.9326.41Price / Sales46.0180.44452.3586.56Price / CashN/A18.4125.8129.91Price / Book12.1710.9313.256.28Net Income-$12.33M-$26.48M$3.29B$270.38M Obalon Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OBLNObalon TherapeuticsN/A$7.30-3.2%N/A+4,250.4%$73.16M$1.59M-5.412Gap DownCATXPerspective Therapeutics2.1354 of 5 stars$3.37-1.7%$12.56+272.6%-77.0%$250.27MN/A0.0070Positive NewsINFUInfuSystem3.1113 of 5 stars$10.42+1.6%$12.50+20.0%+53.5%$212.84M$139.89M173.70410Positive NewsNSPRInspireMD3.6376 of 5 stars$2.46+2.5%$4.50+82.9%-12.6%$102.63M$7.07M-3.2850News CoveragePositive NewsShort Interest ↓Gap UpCTCXCarmellN/A$2.43-4.7%N/A+307.7%$50.80M$32.84K0.0014HSAQHealth Sciences Acquisitions Co. 2N/A$2.73-0.7%N/A-55.8%$30.61MN/A0.004GBSGBSN/A$1.65+6.1%N/A-10.5%$24.49MN/A-2.947RVPRetractable Technologies1.2347 of 5 stars$0.81+1.6%N/A-9.7%$23.83M$38.16M-1.50240Short Interest ↑PETVPetVivoN/A$0.85+3.2%N/A+50.8%$22.99M$1.05M-1.8920News CoverageGap UpBTCYBiotricityN/A$0.61-14.1%N/A+86.4%$17.69M$12.06M-0.5640Gap DownIVFINVO Fertility0.2177 of 5 stars$0.96-4.8%N/A-95.9%$4.41M$6.62M-0.0110 Related Companies and Tools Related Companies CATX Competitors INFU Competitors NSPR Competitors CTCX Competitors HSAQ Competitors GBS Competitors RVP Competitors PETV Competitors BTCY Competitors IVF Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OBLN) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Obalon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Obalon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
